BioReliance Acquires Rights to Big Blue® Colonies and Cell Lines from Agilent

BioReliance Acquires Rights to Big Blue® Colonies and Cell Lines from Agilent

PR Newswire

ST LOUIS, Mo., March 5, 2013

ST LOUIS, Mo., March 5, 2013 /PRNewswire/ --Sigma-Aldrich^® Corporation
(NASDAQ: SIAL) today announced that BioReliance^®
(, the biologics and early development services
business under SAFC^® (, has signed an agreement to acquire
the colonies required for the Big Blue® transgenic rodent mutation (TRM) assay
and to obtain a license to its associated trademark from Agilent Technologies.

TRM assays, which measure mutation frequency in any tissue, are the first in
vivo genetic toxicology mutation assays to be approved by the Organization for
Economic Co-Operation and Development (OECD), meeting Testing Guideline 488.
BioReliance is now the owner of Big Blue^®, mutation models and the exclusive
supplier of testing services based on this model.

"It is often of critical importance to use an in vivo mutation assay in order
to assess human risk in drug development and chemical manufacturing. Big
Blue^® is such an assay and one we are intimately familiar with, having been
part of the initial co-development team in the 1990s," stated Daniel Aparicio,
Executive Director and General Manager of Early Development Services at
BioReliance. "Based on feedback from our customers and from the market in
general, we believe there will be an ever-increasing demand for transgenic
rodent assays and we are delighted to be able to bring that capability to
customers on the back of this agreement."

BioReliance is now focused on completing the transfer of colonies and cell
lines from Agilent and building full capacity and capability to perform the
Big Blue^® assay. BioReliance is in the process of re-qualifying the assay to
meet new regulatory requirements and anticipates that Big Blue^® testing
services will be commercially available in the second half of the year.

BioReliance has been a leading provider of genetic toxicology testing services
over the past two decades and continues to innovate and offer the latest
technologies to help ensure the safety of pharmaceuticals and chemical
compounds. The Big Blue^® Testing Assay was originally validated by
BioReliance to use as a GLP regulatory submission assay to detect chromosomal
and/or gene mutations in collaboration with Agilent in the early 90s.

To learn more about BioReliance by SAFC, please visit:

The foregoing release contains forward-looking statements that can be
identified by terminology such as "will be," "anticipates", "believe" or
similar expressions, or by expressed or implied discussions regarding
potential future revenues from products derived there from. You should not
place undue reliance on these statements. There can be no guarantee that the
products and services in SAFC's product and service offerings will continue to
meet the demands of the marketplace. Nor can there be any guarantee that any
of these products or services will achieve any particular levels of revenue in
the future. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. In particular, management's expectations regarding
these products and services could be affected by, among other things,
unexpected regulatory actions or delays or government regulation generally;
the Company's ability to obtain or maintain patent, trademark or other
proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; the impact that the
foregoing factors could have on the values attributed to the Company's assets
and liabilities as recorded in its consolidated balance sheet, and other risks
and factors referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About BioReliance by SAFC:  BioReliance  was acquired by Sigma-Aldrich
Corporation, in January, 2012 to supply customers access to a powerful,
single-point provider whose products and services span the drug discovery,
development and commercialization pipeline. As part of the SAFC business unit,
BioReliance is a leading provider of cost-effective contract services,
offering more than 1,000 tests or services related to biologics safety
testing, specialized toxicology and animal health services. BioReliance has
over 700 employees and has laboratory operations in Rockville, MD and
Scotland. For more information, visit

About SAFC:  SAFC, the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global specialty
chemicals and biologics supplier. As a trusted manufacturer for the life
science and high technology industries, SAFC works closely with customers to
resolve development challenges and accelerate the product pipeline utilizing
its global "Centers of Excellence" and dedicated manufacturing facilities. Its
rich portfolio includes high-purity inorganic materials for high technology
applications, critical raw materials and extensive biologics safety testing
services for biopharmaceutical manufacturing, and complex, high-potent APIs
and key intermediates for pharmaceutical manufacturing. For more information,

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology SAFC
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

©2013 Sigma-Aldrich Co. LLC. All rights reserved. BioReliance and SAFC are
trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US
and other countries.

SOURCE Sigma-Aldrich Corporation

Contact: Kristi Fortschneider, SAFC, Marketing Communications Coordinator,
+1-314-286-8331 x2407; or Beth Willers, Impress Labs, +1-503-928-7828,
Press spacebar to pause and continue. Press esc to stop.